Nivolumab BMS

RSS

nivolumab

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Nivolumab BMS has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 14/01/2016

Authorisation details

Product details
Name
Nivolumab BMS
Agency product number
EMEA/H/C/003840
Active substance
nivolumab
International non-proprietary name (INN) or common name
nivolumab
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Anatomical therapeutic chemical (ATC) code
L01XC17
Publication details
Marketing-authorisation holder
Bristol-Myers Squibb Pharma EEIG
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
20/07/2015
Contact address

Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Ireland

Product information

30/11/2015 Nivolumab BMS - EMEA/H/C/003840 - -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  • Monoclonal antibodies

Therapeutic indication

Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings